These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 35025707)

  • 21. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
    Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
    N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on inclisiran for the treatment of elevated LDL cholesterol.
    Barkas F; Ray K
    Expert Opin Pharmacother; 2024 Mar; 25(4):349-358. PubMed ID: 38549399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review.
    Merćep I; Friščić N; Strikić D; Reiner Ž
    Cardiovasc Ther; 2022; 2022():8129513. PubMed ID: 35237348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia.
    Ebenezer O; Comoglio P; Wong GK; Tuszynski JA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease.
    Nishikido T
    Cardiovasc Diabetol; 2023 Jan; 22(1):20. PubMed ID: 36717882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.
    Soffer D; Stoekenbroek R; Plakogiannis R
    J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment.
    Kallend D; Stoekenbroek R; He Y; Smith PF; Wijngaard P
    J Clin Lipidol; 2022; 16(2):208-219. PubMed ID: 35168913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translational Population-Pharmacodynamic Modeling of a Novel Long-Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia.
    Gosselin NH; Schuck VJA; Barriere O; Kulmatycki K; Margolskee A; Smith P; He Y
    Clin Pharmacol Ther; 2023 Feb; 113(2):328-338. PubMed ID: 36281788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First clinical experiences with inclisiran in a real-world setting.
    Mulder JWCM; Galema-Boers AMH; Roeters van Lennep JE
    J Clin Lipidol; 2023; 17(6):818-827. PubMed ID: 37775462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.
    Brandts J; Ray KK
    Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
    Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M
    Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
    Fitzgerald K; White S; Borodovsky A; Bettencourt BR; Strahs A; Clausen V; Wijngaard P; Horton JD; Taubel J; Brooks A; Fernando C; Kauffman RS; Kallend D; Vaishnaw A; Simon A
    N Engl J Med; 2017 Jan; 376(1):41-51. PubMed ID: 27959715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a).
    Katsiki N; Vrablik M; Banach M; Gouni-Berthold I
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inclisiran and cardiovascular events: a comprehensive review of efficacy, safety, and future perspectives.
    Mohamed AA; Ray KK
    Curr Opin Cardiol; 2023 Nov; 38(6):527-532. PubMed ID: 37522763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials.
    Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D
    S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Update on PCSK9 inhibition].
    Katzmann JL; Custodis F; Schirmer SH; Laufs U
    Herz; 2022 Jun; 47(3):196-203. PubMed ID: 35445838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.
    Dutta S; Shah R; Singhal S; Singh S; Piparva K; Katoch CDS
    Expert Opin Drug Saf; 2024 Feb; 23(2):187-198. PubMed ID: 38063346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.